Tesamorelin is a stabilized synthetic analog of growth hormone-releasing hormone consisting of the complete 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus. This modification confers resistance to dipeptidyl peptidase IV (DPP-IV) degradation, extending the half-life compared to native GHRH and unmodified analogs like sermorelin.
Visceral Adipose Tissue Research
Tesamorelin is one of the most extensively studied GHRH analogs for visceral fat reduction. The FDA approved tesamorelin (Egrifta) for HIV-associated lipodystrophy, making it one of the few peptides in this class with a regulated clinical track record. Research outside this indication has examined its effects on visceral adipose tissue in non-HIV populations with metabolic syndrome, non-alcoholic fatty liver disease, and cardiovascular risk profiles.
IGF-1 and Metabolic Markers
Tesamorelin consistently elevates IGF-1 levels in research subjects, typically by 60-100% above baseline. Changes in triglycerides, trunk fat percentage, and waist circumference have been primary endpoints in multiple controlled trials. Insulin sensitivity data are mixed, with some studies showing improvements and others showing neutrality, likely influenced by baseline metabolic status of subjects.
Cognitive Research
An emerging area of tesamorelin research involves cognitive function. A randomized controlled trial published in JAMA Neurology (2018) reported improved verbal memory and executive function scores in older adults receiving tesamorelin compared to placebo over 20 weeks. The proposed mechanism involves IGF-1-mediated neurotrophic effects and reduced amyloid deposition, though this area requires further replication.
Comparison with Sermorelin
Both are GHRH analogs but tesamorelin contains the full 44-amino acid sequence versus sermorelin at 29 amino acids. Tesamorelin has a longer half-life due to DPP-IV resistance, produces more sustained GH and IGF-1 elevation, and has a stronger visceral fat reduction signal in the literature. Sermorelin more closely mimics pulsatile GHRH patterns.
For in vitro research use only. Not for human or veterinary use, therapeutic, or diagnostic purposes.